FULC
Fulcrum Therapeutics, Inc.NASDAQHealthcare$8.04+7.49%ClosedMarket Cap: $435.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.42
P/S
0.00
EV/EBITDA
-3.05
DCF Value
$3.00
FCF Yield
-14.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-30.2%
ROA
-20.4%
ROIC
-23.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-22.7M | $-20.3M | $-0.31 | — |
| FY 2025 | $0.00 | -Infinity% | $-84.8M | $-74.9M | $-1.18 | — |
| Q3 2025 | $0.00 | NaN% | $-21.9M | $-19.6M | $-0.31 | — |
| Q2 2025 | $0.00 | -Infinity% | $-19.8M | $-17.3M | $-0.28 | — |
| Q1 2025 | $0.00 | NaN% | $-20.4M | $-17.7M | $-0.28 | — |
| Q4 2024 | $0.00 | -Infinity% | $-19.4M | $-16.6M | $-0.31 | — |
| FY 2024 | $80.0M | 20.8% | $-21.9M | $-9.7M | $-0.16 | — |
| Q3 2024 | $0.00 | NaN% | $-25.1M | $-21.7M | $-0.35 | — |
| Q2 2024 | $80.0M | 78.4% | $52.5M | $55.4M | $0.87 | — |
| Q1 2024 | $0.00 | -Infinity% | $-29.8M | $-26.9M | $-0.43 | — |
| Q4 2023 | $871.0K | 41.7% | $-28.0M | $-24.8M | $-0.40 | — |
| FY 2023 | $2.8M | 100.0% | $-110.7M | $-97.3M | $-1.59 | — |